Katica Bajuk Studen1, Ariel Barkan. 1. Division of Metabolism, Endocrinology and Diabetes, 3920 Taubman, SPC 5354, University of Michigan Medical Center, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109-5354, USA.
Abstract
CONTEXT: The pulsatility of GH secretion in acromegaly poses difficulty in ascertaining true daily GH milieu in patients with this disease. Intensive GH sampling [every 10-20 (Q10-20) min for 24 h] is not practical in clinical practice. OBJECTIVE: Our objective was to ascertain reliability of abbreviated sampling protocols to reflect true 24-h mean GH concentrations in patients with acromegaly. DESIGN: An analysis of previously obtained plasma GH profiles was performed. SETTING: The analysis was performed at the General Clinical Research Center at the University of Michigan. PATIENTS: A total of 115 GH profiles obtained in 94 patients with active acromegaly were examined. INTERVENTION: Frequent blood sampling, i.e. Q10-20 min for 24 h, was performed. MAIN OUTCOME MEASURES: Concordance of 24-h mean GH concentrations derived from Q10- to 20-min samplings with abbreviated GH sampling schedules was performed. The study was planned after data collection. RESULTS: All abbreviated schedules of GH sampling correlated well with the true 24-h plasma GH means (i.e. Q10- to 20-min sampling) (R = 0.93-0.98; P < 0.0001 for all). In the GH range more than 20 microg/liter, only 5 and 9-h means had R values more than 0.9. Single GH concentrations less than 1 microg/liter had a positive predictive value of only 0.29, and those with less than 2.5 microg/liter had a positive predictive value of 0.67 vs. their corresponding 24-h mean GH values of the same magnitude. CONCLUSIONS: The intensity of GH sampling in patients with acromegaly may vary depending on the nature of the required information. Investigators and clinicians should be aware of the limitations of the abbreviated GH sampling protocols in acromegaly.
CONTEXT: The pulsatility of GH secretion in acromegaly poses difficulty in ascertaining true daily GH milieu in patients with this disease. Intensive GH sampling [every 10-20 (Q10-20) min for 24 h] is not practical in clinical practice. OBJECTIVE: Our objective was to ascertain reliability of abbreviated sampling protocols to reflect true 24-h mean GH concentrations in patients with acromegaly. DESIGN: An analysis of previously obtained plasma GH profiles was performed. SETTING: The analysis was performed at the General Clinical Research Center at the University of Michigan. PATIENTS: A total of 115 GH profiles obtained in 94 patients with active acromegaly were examined. INTERVENTION: Frequent blood sampling, i.e. Q10-20 min for 24 h, was performed. MAIN OUTCOME MEASURES: Concordance of 24-h mean GH concentrations derived from Q10- to 20-min samplings with abbreviated GH sampling schedules was performed. The study was planned after data collection. RESULTS: All abbreviated schedules of GH sampling correlated well with the true 24-h plasma GH means (i.e. Q10- to 20-min sampling) (R = 0.93-0.98; P < 0.0001 for all). In the GH range more than 20 microg/liter, only 5 and 9-h means had R values more than 0.9. Single GH concentrations less than 1 microg/liter had a positive predictive value of only 0.29, and those with less than 2.5 microg/liter had a positive predictive value of 0.67 vs. their corresponding 24-h mean GH values of the same magnitude. CONCLUSIONS: The intensity of GH sampling in patients with acromegaly may vary depending on the nature of the required information. Investigators and clinicians should be aware of the limitations of the abbreviated GH sampling protocols in acromegaly.
Authors: P De; D A Rees; N Davies; R John; J Neal; R G Mills; J Vafidis; J S Davies; M F Scanlon Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958
Authors: S Melmed; F F Casanueva; F Cavagnini; P Chanson; L Frohman; A Grossman; K Ho; D Kleinberg; S Lamberts; E Laws; G Lombardi; M L Vance; K Von Werder; J Wass; A Giustina Journal: J Clin Endocrinol Metab Date: 2002-09 Impact factor: 5.958
Authors: G A Kaltsas; A M Isidori; D Florakis; P J Trainer; C Camacho-Hubner; F Afshar; I Sabin; J P Jenkins; S L Chew; J P Monson; G M Besser; A B Grossman Journal: J Clin Endocrinol Metab Date: 2001-04 Impact factor: 5.958
Authors: Eleni V Dimaraki; Craig A Jaffe; Roberta DeMott-Friberg; William F Chandler; Ariel L Barkan Journal: J Clin Endocrinol Metab Date: 2002-08 Impact factor: 5.958
Authors: Alison M Boyce; McKinley Glover; Marilyn H Kelly; Beth A Brillante; John A Butman; Edmond J Fitzgibbon; Carmen C Brewer; Christopher K Zalewski; Carolee M Cutler Peck; H Jeffrey Kim; Michael T Collins Journal: J Clin Endocrinol Metab Date: 2012-10-23 Impact factor: 5.958
Authors: Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers Journal: Endocr Relat Cancer Date: 2017-07-21 Impact factor: 5.678
Authors: C Bona; N Prencipe; A M Berton; F Bioletto; M Parasiliti-Caprino; V Gasco; E Ghigo; S Grottoli Journal: J Endocrinol Invest Date: 2022-06-24 Impact factor: 5.467